September 23, 2013

ETView Medical, Ltd., and Gil Medical, Ltd., (Gil Medical) Execute Distribution Agreement

Agreement allows Gil Medical to exclusively market ETView's VivaSight™ products in Israel.

( September 23 Tel Aviv, Israel ) ETView Medical Ltd. announced today that it has entered into an exclusive distribution agreement with Gil Medical, Ltd., (Gil Medical). The agreement allows CTI to market ETView's VivaSight™ products which combine airway ventilation tubes with integrated continuous high resolution airway imaging for patient airway management and lung isolation capability in Israel a period of two years; other terms were not disclosed.

William Edelman, CEO of ETView Medical commented, “We are excited to add Gil Medical to our expanding distributor network.” Mr. Edelman continued, “VivaSight™ products are distributed in Europe, Asia, and the United States. VivaSight™ provides best-in-class airway management solutions for sophisticated thoracic surgical procedures requiring lung isolation.”

On June 22, 2013, ETView Medical, Ltd., announced an exclusive distribution agreement with MEDITRADE al. s ro, (MEDITRADE) to market ETView's VivaSight™ products in Slovakia, Czech Republic and Poland.

On June 10, 2013, ETView Medical, Ltd., announced an exclusive distribution agreement with Clinical Technologies, Inc., to market ETView's VivaSight™ products in the US states of North Dakota, South Dakota, Nebraska, Kansas, Missouri, Iowa, Minnesota, Wisconsin, Illinois, Kentucky, Indiana, Ohio, Michigan, and West Virginia .

On May 6, 2013, ETView Medical, Ltd., announced an exclusive distribution agreement with Mercury Medical, Inc., to market ETView's VivaSight™ products in Florida, Georgia, South Carolina, North Carolina, Virginia, Maryland, District of Columbia, Tennessee, Arkansas, Alabama, Mississippi, Louisiana, Texas, and Oklahoma.

On March 30, 2013, ETView Medical, Ltd., announced US FDA Clearance of a 510(k) Pre-marketing Notification Application expanding the VivaSight™-DL line of innovative airway devices.

On March 18, 2013, ETView Medical, Ltd. announced State Food and Drug Administration (SFDA, China) Clearance of a Pre-marketing Notification Application for the VivaSight™-SL line of innovative airway devices.

About Gil Medical, Ltd.


According to information provided to the company, Gil Medical, Ltd., was established in 1972 under the name Tzamal Modern Medical Equipment. Today, Gil Medical is a leading Israeli medical equipment importer and distributor. Gil Medical specializes in the importation and distribution for a wide range of medical fields, including: Respiratory Care, Intensive Care, Cardiology, Cardiothoracic, Vascular Surgery, Orthopedics, Dental, and General Hospital Products. Gil Medical has strong bonds with all of Israel’s leading public and private hospitals, outpatient clinics and healthcare funds.

About ETView Medical, Ltd.


ETView Medical Ltd. has successfully combined airway management with continuous direct airway visualization for medical professionals. ETView's patented VivaSight™1  airway management portfolio consists of single-use disposable single and double lumen ventilation tubes with an integrated continuous high resolution airway imaging system. VivaSight™-SL and VivaSight™-DL are currently sold in Europe, Israel, and the US to overcome current limitations and associated adverse surgical events during lung isolation surgeries. Lung isolation is employed to provide one-lung ventilation in patients undergoing thoracic, cardiac, vascular, or esophageal surgeries2.  

Typically, during lung isolation, temporary visualization of the patient airway is achieved with a fiberoptic bronchoscope while the patient is ventilated and the target lung isolated.3 Such intra-operative surgical maneuvers often require repeated imaging and partial blocking of the airway to maintain lung isolation.   It is estimated that over 1.9 million lung isolation procedures are conducted worldwide annually,4  accounting for over $250 million in single-use medical disposables.5  ETView has developed the VivaSight™ platform, combining an airway ventilation tube with integrated continuous high resolution airway imaging for patient airway management and lung isolation capability, eliminating the need for fiberoptic bronchoscope  imaging for intubation and airway monitoring in lung isolation procedures.

Forward-Looking Statement


The Company estimations in this press release, including those estimations regarding the Company's predicted scope of business, constitute forward-looking statements, as such term is defined under the Israeli Securities Law (5728-1968), and there is no certainty that such estimations shall materialize. The Company's estimations are based on business assumptions, prior experience, and professional data. Due to various factors, foreseen and unforeseen, including, but not limited to, changes in market trends, competition, global or local economic conditions, and amendments of regulation, such estimations may not materialize in whole or in part, or materialize in a substantially different manner than anticipated by the Company.

1Patents issued and pending
2Principles and Practices of Anesthesia for Thoracic Surgery. P. Singer (ed.) 2011
3Anesthesia & Analgesia. 2009;108:1097–101
4National Health Statistics Reports Number 29, October 26, 2010
5Company estimates on file
6Minerva Anestesiol. 2009;75 (Suppl 1):1-4.